ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 77 filers reported holding ALDEYRA THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,664,088 | -38.2% | 249,115 | -22.4% | 0.00% | – |
Q2 2023 | $2,693,426 | -77.0% | 321,028 | -72.8% | 0.00% | -100.0% |
Q1 2023 | $11,717,032 | +434.0% | 1,179,963 | +274.3% | 0.00% | – |
Q4 2022 | $2,194,139 | +35.8% | 315,250 | +4.2% | 0.00% | – |
Q3 2022 | $1,616,000 | +11.1% | 302,643 | -17.1% | 0.00% | – |
Q2 2022 | $1,455,000 | -7.3% | 364,960 | +3.3% | 0.00% | – |
Q1 2022 | $1,570,000 | +126.6% | 353,150 | +103.9% | 0.00% | – |
Q4 2021 | $693,000 | +43.5% | 173,204 | +214.2% | 0.00% | – |
Q3 2021 | $483,000 | -53.6% | 55,120 | -39.9% | 0.00% | – |
Q2 2021 | $1,040,000 | +436.1% | 91,747 | +460.3% | 0.00% | – |
Q1 2021 | $194,000 | +123.0% | 16,375 | +29.0% | 0.00% | – |
Q4 2020 | $87,000 | +117.5% | 12,695 | +135.1% | 0.00% | – |
Q3 2020 | $40,000 | -95.6% | 5,400 | -97.5% | 0.00% | – |
Q2 2020 | $908,000 | +22600.0% | 217,766 | +11440.3% | 0.00% | – |
Q1 2020 | $4,000 | -97.9% | 1,887 | -94.3% | 0.00% | – |
Q4 2019 | $191,000 | +282.0% | 32,876 | +250.4% | 0.00% | – |
Q3 2019 | $50,000 | +257.1% | 9,383 | +313.5% | 0.00% | – |
Q2 2019 | $14,000 | -73.6% | 2,269 | -61.1% | 0.00% | – |
Q1 2019 | $53,000 | -81.0% | 5,839 | -82.6% | 0.00% | – |
Q4 2018 | $279,000 | -44.2% | 33,617 | -7.2% | 0.00% | – |
Q3 2018 | $500,000 | +47.1% | 36,226 | -15.3% | 0.00% | – |
Q2 2018 | $340,000 | +206.3% | 42,772 | +189.1% | 0.00% | – |
Q1 2018 | $111,000 | +60.9% | 14,796 | +46.4% | 0.00% | – |
Q4 2017 | $69,000 | -2.8% | 10,110 | +3.3% | 0.00% | – |
Q3 2017 | $71,000 | +446.2% | 9,783 | +249.9% | 0.00% | – |
Q2 2017 | $13,000 | -53.6% | 2,796 | -49.9% | 0.00% | – |
Q1 2017 | $28,000 | -12.5% | 5,586 | -6.3% | 0.00% | – |
Q4 2016 | $32,000 | -8.6% | 5,964 | +33.7% | 0.00% | – |
Q3 2016 | $35,000 | +59.1% | 4,460 | +14.7% | 0.00% | – |
Q2 2016 | $22,000 | +46.7% | 3,887 | +8.3% | 0.00% | – |
Q1 2016 | $15,000 | -69.4% | 3,589 | -50.3% | 0.00% | – |
Q4 2015 | $49,000 | -58.8% | 7,222 | -64.8% | 0.00% | – |
Q3 2015 | $119,000 | -7.0% | 20,496 | +24.2% | 0.00% | – |
Q2 2015 | $128,000 | -9.2% | 16,504 | +19.2% | 0.00% | – |
Q1 2015 | $141,000 | +1466.7% | 13,841 | +964.7% | 0.00% | – |
Q4 2014 | $9,000 | – | 1,300 | +14344.4% | 0.00% | – |
Q2 2014 | $0 | – | 9 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 908,488 | $6,232,000 | 2.88% |
Knoll Capital Management, LLC | 569,405 | $3,906,000 | 2.66% |
Mesirow Financial Investment Management, Inc. | 64,698 | $443,828,000 | 1.40% |
Ghost Tree Capital, LLC | 650,000 | $4,459,000 | 0.99% |
Johnson & Johnson Innovation - JJDC, Inc. | 594,834 | $4,081,000 | 0.53% |
Perceptive Advisors | 6,285,458 | $43,118,000 | 0.46% |
Affinity Asset Advisors, LLC | 100,000 | $686,000 | 0.36% |
ACUTA CAPITAL PARTNERS, LLC | 192,500 | $1,321,000 | 0.36% |
Avidity Partners Management LP | 1,435,000 | $9,844,000 | 0.32% |
APOGEM CAPITAL LLC | 55,821 | $383,000 | 0.26% |